A fi­nal flop sig­nals the bit­ter end to Cir­cas­sia’s big plans for al­ler­gy R&D

Re­mem­ber the big plans Cir­cas­sia {LSE: CIR} had for its al­ler­gy drug pipeline when it went pub­lic, rais­ing $333 mil­lion in 2014 with promis­es of big things to come for in­vestors?

It didn’t work out. In fact, it was a com­plete bust.

Their Phase IIb has now wrapped for a house dust mite al­ler­gy rem­e­dy, and it failed like the rest of the stud­ies. So Ox­ford, UK-based Cir­cas­sia is pack­ing it in, and switch­ing over to a res­cue strat­e­gy pre­sent­ed by As­traZeneca.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Senior Associate

Alexandria Real Estate Equities

Durham, NC, USA